Skip to main content
. 2020 Oct 26;7(2):111–119. doi: 10.1159/000512270

Table 4.

Treatment during hospitalization in critically ill COVID-19 patients

All patients n = 119 Non-AKI n = 68 Mild AKI n = 17 Severe AKI n = 34
ACEI or ARB, n (%) 6 (5) 4 (5.9) 2 (11.8) 0
Antibiotics, n (%) 110 (92.4) 62 (91.2) 16 (94.1) 32 (94.1)
Antivirus, n (%) 88 (73.9) 51 (75) 13 (76.5) 24 (70.6)
Antidiabetic, n (%) 41 (34.5) 19 (27.9) 6 (35.3) 16 (47.1)
Diuretic, n (%) 78 (65.5) 38 (55.9) 13 (76.5) 27 (79.4)
Glucocorticoid, n (%) 89 (74.8) 50 (73.5) 10 (58.8) 29 (85.3)

AKI, acute kidney injury; COVID-19, coronavirus disease 2019; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker.